Search results
Showing 331 to 345 of 384 results for kidney
Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia (CG157)
This guidance has been updated and replaced by NICE guideline NG203.
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)
This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.
This evidence summary has been updated and replaced by NICE guideline NG203.
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)
Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.
Past technology appraisal appeals and decisions
NICE has developed a medtech innovation briefing (MIB) on MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery .
NephroCheck test to help assess the risk of acute kidney injury in critically ill patients (MIB156)
This medtech innovation briefing has been updated and replaced by NICE HealthTech guidance 544.
We have moved Medical technologies guidance 60 to become HealthTech guidance 594. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.
NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .
We have moved Diagnostics guidance 29 to become HealthTech guidance 441. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.